Grifols S.A. (GRF.MC) — Quality & forensics
As of 2026-09-18 — refreshed nightly. Closelook readings from an investment research diary, not ratings or advice.
The Closelook module scores
- Valuation 79
- Quality 43
- Growth 39
- Balance sheet 34
- Cash quality 53
- Capital allocation 52
- Momentum 45
Scores are computed nightly across the coverage universe and read relative to it — the methodology lives in the company-scoring explainer.
Financial forensics — the academic screens
Sits in the distress zone (below 1.81). The Z-Score estimates financial-distress risk from five balance-sheet and earnings ratios.
Nine binary fundamental-strength checks across profitability, leverage and operating efficiency.
Screens reported earnings for statistical manipulation patterns — below the −1.78 manipulation-risk threshold. A screen, not an accusation.
Continue: the GRF.MC chart & overview
FAQ · from the current data · as of 2026-09-18
Quick answers
What is Grifols S.A.'s Closelook quality reading?
The composite reads 48/100 across 7 modules, as of 2026-09-18: valuation 79, quality 43, growth 39, balance sheet 34, cash quality 53, capital allocation 52, momentum 45. Closelook scores are research diary readings, not ratings or investment advice.
What is Grifols S.A.'s Altman Z-Score?
1.12, which sits in the distress zone (below 1.81) as of 2026-09-18. The Altman Z-Score estimates financial distress risk from five balance-sheet and earnings ratios.
What is Grifols S.A.'s Piotroski F-Score?
5 of 9, as of 2026-09-18. The F-Score counts nine binary fundamental-strength signals across profitability, leverage and operating efficiency.
What does Grifols S.A.'s Beneish M-Score indicate?
-2.44 — below the −1.78 manipulation-risk threshold, as of 2026-09-18. The M-Score screens reported earnings for statistical manipulation patterns; it is a screen, not an accusation.
Related in the Closelook universe
then Drug Manufacturers - General, then Healthcare. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.
- LLY Eli Lilly and Companyindustry
- ORNAV.HE Orion Oyj Aindustry
- ORNBV.HE Orion Oyj Bindustry
- SAN.PA Sanofi SAindustry
- NVO Novo Nordisk A/Sindustry
- AMGN Amgen Incindustry
- GILD Gilead Sciences Incindustry
- MRK Merck & Company Incindustry
- PFE Pfizer Incindustry
- ABBV AbbVie Incindustry
- JNJ Johnson & Johnsonindustry
- BIIB Biogen Incindustry
- OGN Organon & Coindustry
- BMY Bristol-Myers Squibb Companyindustry
- GSK GlaxoSmithKline PLC ADRindustry
- SNY Sanofi ADRindustry
- AZN AstraZeneca PLCindustry
- ROVI.MC Laboratorios Farmaceuticos ROVIsector
- ALM.MC Almirall S.A.sector
- BION.SW BB Biotech AGsector